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CMR and LV Noncompaction*
Does it Matter How We Measure Trabeculations?Steffen E. Petersen, MD, DPHILLondon, United KingdomLeft ventricular noncompaction (LVNC) is an
intriguing, but poorly understood, condition that
can lead to heart failure, malignant arrhythmias, and
thromboembolic events. It can be associated with
neuromuscular disorders and can coexist with other
cardiac malformations (1).See page 931Diagnostic imaging criteria were ﬁrst described for
native echocardiography by Chin et al. (2), Jenni
et al. (3), and Stöllberger et al. (1) and followed by
cardiac magnetic resonance (CMR) criteria proposed
by Petersen et al. (4) and Jacquier et al. (5). It is
important to emphasize here that currently there is
no diagnostic tool, neither genetic nor imaging, that
can, in all patients, reveal the underlying truth of
whether or not somebody is affected by LVNC. The
absence of such a “gold standard” is the main reason
why all cardiac imaging studies have limitations when
attempting to determine their diagnostic accuracies
with a basis of a likely diagnosis of LVNC and not a
deﬁnitive diagnosis. To avoid a circular argument in
diagnostic accuracy studies for LVNC, the imaging
ﬁndings alone should not be considered sufﬁcient for
a diagnosis of LVNC but should be supported with
evidence of malignant arrhythmias, neuromuscular*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
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Cardiovascular Imaging.disorders, or a family history of LVNC or throm-
boembolic events. Another observation holds true
for most LVNC diagnostic accuracy studies: in a
derivation dataset, cutoff values for continuous vari-
ables, such as the noncompaction-to-compaction
ratio, are typically determined using receiver-
operating characteristics curves and tradeoff sensi-
tivity and speciﬁcity according to the purpose of the
test; rarely is the diagnostic accuracy of a cutoff value
validated in a validation dataset.
Sensitivity and speciﬁcity are independent of the
prevalence of disease. A useful diagnostic test pro-
vides information that changes the likelihood of
having a disease (post-test probability) from the
likelihood of having disease without the test infor-
mation (pre-test probability). The positive and
negative predictive values quantify this information
of the test as a function of sensitivity, speciﬁcity, and
pre-test probability (this may be the prevalence of
disease). Figure 1 represents the relationships be-
tween pre- and post-test probabilities over the entire
range of pre-test probabilities given the sensitivities
and speciﬁcities published (4,5). An uninformative
test (50% sensitivity and 50% speciﬁcity) does not
change the probabilities and equals the identity line
(45 line) in Figure 1. The graph also shows that in
the range of pre-test probabilities that are consistent
with the currently published range of LVNC prev-
alence (0.014% to 0.05%) (6), both CMR criteria do
not provide sufﬁcient diagnostic information, as the
post-test probability remains low. Both CMR
criteria help to reﬁne the post-test probability in the
low and intermediate pre-test range. Above a pre-
test probability of 10%, the post-test probability is
above 90% for the Petersen criteria, showing the
value of CMR as a rule-in test in such a population.
Similarly, the negative CMR test result in the same
population reduced the post-test probabilities to very
Figure 1. Relationship Between Pre- and Post-Test Probability for Published
Sensitivities and Speciﬁcities to Diagnose LVNC
Petersen criteria: sensitivity: 86%; speciﬁcity: 99%. Jacquier criteria: sensitivity: 93.7%;
speciﬁcity: 93.7%. An uninformative test has a sensitivity and speciﬁcity of 50%. In very low
pre-test probabilities consistent with the reported left ventricular noncompaction (LVNC)
prevalence of 0.014% to 0.5%, neither cardiac magnetic resonance (CMR) criteria are
very informative. In low and intermediate pre-test probabilities both CMR criteria are
informative, one slightly better at ruling out disease and one better at ruling in disease.
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942low likelihoods and thus underlines its potential use
as a rule-out test.
Currently no prediction rule is available based on
the above clinical information to determine the pre-
test probability for LVNC. Patients with a family
history of LVNC, known LVNC complications,
associated muscular disorders, or regional wall motion
abnormalities would have higher than background
prevalence pre-test probabilities of having LVNC. To
illustrate the use of CMR in diagnosing or excluding
LVNC in intermediate probabilities, consider the
following CMR screening in a family with an auto-
somal dominant inheritance pattern. The nephew of
an index patient has a pre-test probability of 25%
compared with that of the index patient’s child, which
is 50%. Here, positive CMR scans using Petersen
criteria lead to post-test probabilities of having LVNC
of 96.6% and 98.9%, respectively. Negative CMR
scans lead to post-test probabilities of having LVNC
of 4.5% and 12.4% (4).
The clinical value of CMR in the diagnosis of
LVNC is currently unclear due to a lack of pro-
spective population-based studies including cardiac
imaging and LVNC cohorts. The natural history of
LVNC with normal ejection fraction compared to
normally functioning and normally trabeculated
hearts remains unknown, and the natural history of
LVNC with impaired LV systolic function
compared to that in matched dilated cardiomyopathy
patients is unclear. This information could inform
how to best manage such patients. Many openquestions remain, such as: should patients with
heavily trabeculated hearts and normal function be
treated to reduce the likelihood of adverse remodel-
ling or thromboembolic events? And should LVNC
patients with impaired systolic function be managed
differently from those with dilated cardiomyopathy?
In this issue of iJACC, Stacey et al. (7) present,
for a number of diagnostic CMR criteria that are
similar but slightly modiﬁed compared to those in
previously published studies, associations with
prevalent (existing) heart failure and with incident
(future) combined clinical events (death, heart fail-
ure readmission, embolic events, or ventricular ar-
rhythmias). The motivation for this retrospective
study with chart reviews to determine outcomes was
to investigate whether end-systolic measures of
LVNC are feasible and can improve clinical recog-
nition of LVNC. A total of 122 patients (2.5%
of the 4,762 patients screened) were included as
reports mention trabeculations or LVNC. The
authors ﬁnd that measures of end-systolic non-
compaction-to-compaction ratios (ES-NCCR) are
the strongest predictors of not only prevalent
heart failure (adjusted odds ratio: 29.4; conﬁdence
interval [CI]: 6.6 to 125) but also incident com-
bined clinical events (adjusted odds ratio: 8.6;
CI: 2.5 to 33), albeit with very wide CIs, reﬂecting
uncertainty. This study is welcomed as it provides
some much-needed insight into the not entirely
benign natural history of some patients with a
LVNC diagnosis based on the CMR ﬁndings.
However, no ﬁrm conclusions can be drawn as to
whether ES-NCCR is superior to end-diastolic
measures for the diagnosis of LVNC leading to
related events. Given the above explanations
regarding the relationship of pre- and post-test
probabilities of LVNC and the arguments pre-
sented in Figure 1, it is likely that a large proportion
of the so-called LVNC population does not have
the disease. In particular, patients with normal
ejection fraction may have no disease. It is possible
that ES-NCCR may identify LVNC patients with
more pronounced impairment of regional or global
dysfunction due to the reduced contraction of the
trabeculations. Whether this approach is superior to
using a diastolic measure with attention to regional
and global function is unclear. Even though the
authors adjusted the odds ratios for covariates
including heart failure, it is possible that the
adjusted odds ratios for end-systolic parameters
were higher compared with the end-diastolic ones
due to the lack of contraction of trabeculations
when ejection fraction was impaired. Whether end-
systolic parameters are more useful in diagnosing
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943LVNC or predicting clinical events in normal ejec-
tion fraction remains unclear.
The study by Stacey et al. (7) was limited by its
retrospective nature and relatively small sample size,
leaving it unable to provide sufﬁcient information
on the natural history of patients with normal
ejection fraction and impaired ejection fraction
separately (and to compare the latter group to
dilated cardiomyopathy patients).
Prospective studies are needed to document the
natural progression of LVNC and to determine
clinical and imaging predictors of adverse outcomes,which could be the basis for a simple diagnostic
prediction rule. This is a task for a coordinated
effort between the international imaging and heart
muscle disease communities to come together to
plan, raise funds for, and organize such a study.Reprint requests and correspondence: Dr. Steffen E.
Petersen, Advanced Cardiovascular Imaging, William
Harvey Research Institute, National Institute for Health
Research, Cardiovascular Biomedical Research Unit at
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